Fig. 4.

Bortezomib promotes cisplatin/MTA efficacy in chemotherapy-resistant MPM cells. a, b Clonogenic assay of 2D and 3D MESO-1 cells after treated with the indicated drugs. Colonies were stained (a) and quantified (b) after 7 days. Data are presented as mean ± s.d. (n = 3). **P < 0.01, ***P < 0.001 by unpaired two-sided t-test. ns, not significant. c Viability of 2D and 3D cells after 72 h treatment with chemotherapy (1 μM cisplatin + 1 μM MTA) alone or combined with bortezomib (1, 10, 100 nM). Data are shown as mean ± s.d. (n = 3). **P < 0.01, ***P < 0.001 by unpaired two-sided t-test. d FACS-based apoptotic assay of 3D cells after treated for 48 h with chemotherapy (1 μM cisplatin + 1 μM MTA), bortezomib (10 nM) or the combination